Whitehawk Therapeutics (WHWK) Stock Analysis & AI Equity Report
Whitehawk Therapeutics (WHWK) overview
Whitehawk Therapeutics (WHWK) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 7.1m and operating profit of USD -114m; the year-end share price was 2.42 USD and market capitalisation was USD 114m. Whitehawk Therapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Whitehawk Therapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Whitehawk Therapeutics
Whitehawk Therapeutics is a clinical-stage oncology therapeutics company developing antibody-drug conjugates for cancer. Its licensed pipeline includes candidates targeting PTK7, MUC16, and SEZ6, using a linker-payload platform designed to deliver a topoisomerase I inhibitor into cancer cells. Whitehawk’s lead candidates are in early clinical development for solid tumors, including lung, ovarian, and endometrial cancers.
Generate the Whitehawk Therapeutics report
Whitehawk Therapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Whitehawk Therapeutics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Whitehawk Therapeutics
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.